POR and phenylketonuria: We previously demonstrated that Cypor-aiming CRISPR–Cas9-mediated gene editing in healthy hepatocytes using nonviral delivery, coupled with transient APAP administration for the expansion of gene-edited hepatocytes in the liver, could cure a mouse model of PKU.